2009, Number 10
PDF size: 218.85 Kb.
ABSTRACTThe primary objective in metastatic breast cancer is tumor control and symptom palliation. Factors to be considered are: efficacy, tolerance and quality of life as well as patient preferences. In the Hormone Receptor Positive Group, Hormonal treatment is the best choice because of it´s effectiveness and good toxicity profile. Endocrine therapy has two main targets: the first one is to block estrogen production. In premenopausal women this can be through ovarian ablation. In postmenopausal women this is achieved by blocking the peripheral conversion of androgens to estrogens by blocking the enzyme known as aromatase. The other option is to block the action of the estrogen on it´s receptor with the group of drugs known as selective estrogen receptor modulators (SERM). This class of drugs can be used in pre and postmenopausal women. Treatment should be tailored according to patient characteristics and menopausal status.
Fallowfield L. Evolution of breast cancer treatments: current options and quality-of life considerations. Eur J Oncol Nursing 2004;8:S37-S82.
Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001;28:291-304.
Rubens RD, Bajetta E, Bonneterre J, Klijn JG, et al. Treatment of relapse of breast cancer after adjuvant systemic therapy. Eur J Cancer 1994;30A:106-11.
Ravdin PM, Green S, Dorr TM, McGuire WL, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-91.
Klijn JG, Blarney RW, Boccardo F, Tominaga T, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer. A meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53.
Kuss JT, Muss HB, Hoen H, Case LD. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Trest 1997;42:265-74.
Saez RA. In: Kennedy BJ, editor. Current clinical oncology. 1st ed. New York: Wiley-Liss, 1989;pp:163-72.
Bonneterre J, Buzdar A, Nabholtz JM, Robertson JS, et al. Anastrozole is superior to tamoxifen as first line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, et al. Phase III study of letrozole versus tamoxifen as firstline therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21(11):2101-9.
Nabholtz SM, Buzdar A, Pollak M, Harwn W, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a NorthAmerican multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-67.
Robertson JF, Osborne CK, Howell A, Jones SE, et al. Fulvestrant versus anastrozole for the treatment of advanced breast arcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-38.
Kaufman M, Bajetta E, Dirix LY, Fein LE, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-411.
Paridaens R. Exemestan vs tamoxifen. In: Silva OE, Surrida S, editors. Brustkrebs. Diagnostik und therapy. 4th ed. Hamburg: Elsevier Urban & Fisher, 2004;p:241.
23rd Annual San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 2000:64:27.
Prowell T M, Davidson NE. What Is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Tue Oncologist 2004;9:507-17.
Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocri Relat Cancer 2006;13:689-706.
Davidson NE. Ovarian ablation as treatment for young women with breast cancer. J Natl Cancer Inst Monogr 1994;16:95-99.